Zinc is an essential micronutrient for growth and proper immune function. There is currently no simple recommendation for the assessment of population-level zinc deficiency. Trials of zinc supplementation have shown positive effects of supplementation on clinical outcomes and growth. We reviewed the results of randomized trials of zinc supplementation and correlation studies that assessed infectious diseases, growth, and development outcomes among children under 5 years of age. The results indicate that zinc supplementation decreases the incidence and prevalence of diarrhea and pneumonia, but the use of trial data to make population-level estimates of zinc deficiency is not practical and is difficult to quantify. The data also indicate that zinc supplementation increases growth, especially among children who are stunted. Stunting rates are commonly estimated and can be used to estimate zinc deficiency. Previous recommendations suggest that stunting rates at or above 20% should be indicative of zinc deficiency among children under 5 years of age. This review provides additional data and analysis to support the current recommendation.
Introduction
Since the 1960s [1] , severe zinc deficiency has been recognized as a major cause of growth retardation and delayed sexual maturation. Although these signs are easily recognizable when zinc deficiency is severe, the diagnosis becomes more difficult in young children who are moderately deficient and in children who have multiple nutritional deficiencies. Serum zinc is the most commonly assessed individual indicator of zinc status; however, it is not widely accepted as an accurate measure of true zinc status because its value is influenced by recent dietary intake and infection [2, 3] . On a population level, it has been proposed that assessing potential zinc intake based on food-balance sheets may be a way to assess the zinc status of a population [4] , but this method generalizes for the entire population and does not allow for variation according to subgroup of the population.
Reports of trials assessing the effects of zinc given as a daily or weekly supplement have shown benefits when it is given short-term for diarrhea treatment [5] , potential benefits when it is given short-term for pneumonia treatment [6] , and positive effects of ongoing supplementation for the prevention of infectious diseases and improved growth in some populations [7, 8] . Enrollment in these studies was not dependent upon a biochemical assessment of individual zinc status, and many trials have observed positive effects of supplementation on the functional indicator assessed. Given that there is currently no simple method for assessing zinc status, we sought to determine if zinc deficiency could be assessed by measuring functional indicators such as basic rates of diarrhea and pneumonia infection, growth, and development.
In this review we present the results from randomized, controlled trials of zinc supplementation for the prevention and treatment of infectious diseases, growth retardation, and developmental delays, and nonrandomized studies demonstrating a correlation of biochemical zinc status with one of the functional indicators of interest. We conducted a literature search of PubMed using the key word phrases zinc and diarrhea; zinc and pneumonia; zinc and malaria; zinc and growth; and zinc and development. We searched only for studies of children and only for studies published in English.
Studies of all children under 18 years of age were considered for growth outcomes, because prior metaanalysis of these data included all children. Otherwise we limited the studies to those conducted on children under 5 years of age. For randomized trials, only those where a direct comparison between children receiving zinc and those not receiving zinc could be assessed were included; i.e., the zinc group was different from the control group by only zinc, and all other micronutrients were consistent in study groups. Trials with multiple comparison groups were included, but only the zinc and control groups are presented here.
We present a brief summary and a more detailed table of the findings for each functional indicator. In conclusion, we discuss the practicality and effectiveness of using functional indicators to assess individual-and population-level zinc deficiency.
Treatment of infectious diseases

Acute diarrhea
There are 14 trials assessing zinc supplementation for the treatment of diarrhea [9-21] * (table 1). Thirteen of these trials were conducted in South Asia and one was conducted in Brazil. Outcomes assessed included diarrhea duration, stool frequency, stool volume, antibody response, percentage developing persistent diarrhea, weight loss during the episode, fluid intake, and need for an intravenous drip. In all but one trial, zinc supplementation had a positive effect on diarrhea: this trial was unique in that it is the only published study of zinc supplementation for diarrhea treatment in infants under 6 months of age [13] . The treatment dose in all studies was at least two times the recommended dietary allowance (RDA) for children under 5 years of age [22] . In two of the five studies in which serum zinc was measured at baseline, zinc had a greater effect among children who were deficient at baseline [18, 19] .
Persistent diarrhea
Five trials have assessed zinc supplementation in children with persistent diarrhea [23] [24] [25] [26] [27] (table 1) . One trial was conducted in Peru, and four were conducted in South Asia. Outcomes assessed were diarrhea duration, stool frequency, stool weight, and stool volume. Zinc-supplemented children had better diarrhea outcomes in three of the five trials [23, 24, 26] . All zincsupplemented children received at least two times the RDA during the treatment period. Serum zinc was * Roy SK. Zinc supplementation in malnourished Bangladeshi children with cholera (Abstract). In: 10th Asian Conference on Diarhhoeal Disease and Nutrition, 2005. measured in all studies at baseline, but there were no reported differences according to baseline zinc status. One study reported a benefit of zinc supplementation only among boys or those children who were underweight at baseline [26] .
Pneumonia
Zinc has been investigated as an adjunct treatment for pneumonia in three trials [6, 28, 29] (table 1) , all of which were conducted in South Asia. Outcomes assessed were time to recovery from pneumonia symptoms, time to complete recovery, respiratory rate, hospitalization time, oxygen saturation, and difficulty feeding. Children receiving zinc recovered faster from pneumonia than those receiving placebo in two of the three trials [6, 28] . All treatment doses were at least two times the RDA and were given for 5 or 6 days or until the child recovered. Serum zinc was measured at baseline in all studies, and no differences in the effect of treatment according to baseline zinc status were reported.
Malaria
One multisite study assessed the effect of zinc supplementation as adjunct therapy for the treatment of malaria [30] . This study included four sites in Africa and one in Ecuador. Time until fever reduction, time until parasitemia reduction, and hemoglobin concentration were assessed as outcome measures. The zinc dose was at least two times the RDA and was given for 4 days in addition to standard malaria treatment. There was no overall effect of the added zinc on recovery from malaria. Serum zinc was measured at baseline, and no differences according to baseline zinc status were reported.
Prevention of infectious diseases
Short-course trials
Zinc supplementation, when given for 10 to 14 days during a diarrhea episode, has proven to be an effective treatment (table 2) . Several studies have conducted follow-up visits for 2 to 3 months following this treatment to evaluate the effect of a short course of zinc, given at a treatment dose of at least two times the RDA, on the incidence and prevalence of infectious diseases after treatment [11, 31, 32] . In all three studies, zincsupplemented children had fewer episodes of diarrhea during the months following and mixed results for incidence of pneumonia. One study only saw a benefit of zinc supplementation among children who were stunted or underweight at baseline [32] . 
Long-term daily supplementation
Long-term daily zinc supplementation for the prevention of infectious illnesses has been assessed in 21 trials (table 2) . Supplementation in these studies continued for at least 8 weeks, and doses ranged from 5 to 20 mg per day. Outcome measures assessed include incidence and prevalence rates of diarrhea, respiratory tract infections, pyoderma, fever, malaria, ear infections, vomiting, and rashes, as well as rates of hospitalizations and mortality. Nineteen of the 21 trials observed a positive effect of zinc supplementation on at least one outcome measure assessed [33-36, 38-44, 46-54] . Zinc supplementation decreased the incidence of diarrhea by approximately 18% and the prevalence of diarrhea by 25% [8] . For pneumonia, zinc supplementation decreased the incidence by 41% [8] . Ten of these trials assessed serum zinc at baseline, and one assessed hair zinc as well [8, 33, 35, 39-41, 43, 46, 50-52, 54] . Of these trials, two observed greater benefits among children who had lower serum zinc levels at baseline [41, 51] , one study observed a lower prevalence and incidence of diarrhea among children older than 11 months [51] , and one found a larger positive effect of zinc supplementation on the incidence of diarrhea among boys and children with low weight-for-length at baseline [49] . Rates of hospitalization and mortality were not often considered because of the large sample sizes required. However, two studies reported a smaller number of hospitalizations and a shorter duration of stay [47, 48] , and one study reported an overall lower mortality rate in zinc-supplemented children [42] .
Long-term weekly supplementation
Four trials assessed weekly zinc supplementation for at least 2 months for the prevention of infectious diseases (table 2) [38, [55] [56] [57] . Supplementation ranged from 20 to 70 mg, one or two times per week. One study was conducted in Gambia and three were conducted in South Asia. These studies reported the effect of zinc on the incidence of diarrhea, acute lower respiratory tract infections, malaria, the prevalence of diarrhea, and mortality rates. Two of the four trials observed a positive effect of zinc on diarrhea incidence (6% lower in zinc-supplemented children [56] and 40% lower in zinc-supplemented children [38] ). One trial observed a decrease in pneumonia incidence by 17%, as well as fewer deaths among infants supplemented with zinc at a weekly dose of 50 to 70 mg [56] . No trial reported differences according to baseline serum zinc status.
Growth
Zinc supplementation for enhanced growth in children has been widely studied in developing countries where there are high rates of stunting and widespread malnutrition. Twenty-eight trials of children from birth to 17 years of age have been summarized in table 3 [34, 36, 37, 41, 43, 45, 47, 48, 50, [52] [53] [54] [55] [56] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] . Growth outcomes assessed were weight, height, weight-for-age z-score (WAZ), height-for-age z-score (HAZ), weightfor-height z-score (WHZ), mean upper-arm circumference (MUAC), arm span, triceps skinfold thickness (TSF), arm muscle area for age, mid-arm muscle area [72] , head circumference, knee-heel length, and chest circumference. Seven of these trials reported no effect of zinc on any measured indicator [34, 48, 50, 52, 60, 61, 70 ], yet all others reported a positive effect of zinc on at least one measured indicator. Seventeen of the trials assessed serum zinc at baseline, and of those, one reported positive effects only among children who were zinc-deficient at baseline [41] . Growth was previously assessed in a meta-analysis by Brown et al. [7] , which included studies conducted in both developing and developed countries. This metaanalysis rigorously compiled data from both published and unpublished studies and also included several reports not available in English. This comprehensive meta-analysis reported statistically significant effect sizes for height increments (0.35; 95% confidence interval [CI], 0.189 to 0.511) and weight increments (0.309; 95% CI, 0.178 to 0.439) [7] .
This analysis was recently updated for this review to compare the effect size of zinc on height observed in developed versus developing countries. In a separate analysis of only developing countries, the effect sizes for both height and weight were calculated. For these analyses, units were converted to effect size by calculating the "difference between the means of the zinc and control groups divided by their pooled standard deviation" [7] . Figure 1 illustrates the change in effect size observed as the initial mean HAZ score changes. As initial HAZ score improves, the effect size decreases in both developing and developed country studies. This effect size is illustrated by country status and initial HAZ score for all children in figure 2 [43, 45, 47, 48, 50, 52, 53, 55, 58, 59, 62-67, 69, 71, 73-83] . Figure 3 [43, 45, 48, 52, 53, 55, 58, 59, 62-64, 66, 67, 71, 73-75, 79, 82] also illustrates the effect size of zinc on height but includes only children 6 months of age and older. These figures show that there is not an overall difference in effect size between developed countries and less-developed countries for all studies, or for those studies of only children 6 months of age and older. The effect of zinc is greatest among children with low HAZ scores at enrollment; this difference in effect according to HAZ score appears to be more dramatic in older children.
Developing countries: Change in height or length
There was a significant effect of zinc on change in . 4 ) [43, 45, 47, 48, 50, 52, 53, 55, 58, 59, 62-67, 69, 71, 77, 79, 84] . The weighted average effect size was 0.281 (95% CI, 0.195 to 0.367) for the fixed model and 0.355 (95% CI, 0.142 to 0.568) for the random-effects model. Numerous variables were included in bivariate analyses to assess the correlation with the effect size (table 4). Studies that did not monitor dosing and those with more frequent doses had larger effect sizes; but no variable was significant in the backward stepwise randomeffects meta-regression.
Developing countries: Change in weight
There was a significant effect of zinc on change in weight in this meta-analysis (p < .0001) ( fig. 5) [43, 45, 47, 48, 50, 52, 53, 55, 58, 62-67, 69, 71, 77, 79, 84] . The weighted average effect size was 0.302 (95% CI, 0.216 to 0.389) for the fixed model and 0.316 (95% CI, 0.151 to 0.482) for the random-effects model. Selected variables were included in bivariate analyses assessing the relation of these with the effect size of zinc on weight (table 5). As was observed with the analyses of height or length described above, studies that did not monitor dosing and those that used more frequent dosing had larger effect sizes. When variables were removed from Effect size [ [90] . Five out of seven trials showed some benefit of zinc on at least one measured indicator [34, 61, [86] [87] [88] , one trial observed a negative effect of zinc on the mental development index of the BSID [89] , and one trial observed no effect [85] . 
Correlation studies
We included studies with cohort, cross-sectional, or case-control designs that assessed a biochemical measure of zinc status and one of the functional indicators we have included in this review (table 7) . Two cohort studies assessed serum zinc at baseline, and one found that lower serum zinc status was associated with increased infection rates during the 90 days of follow-up [91, 92] . Three cross-sectional studies assessed correlations of serum zinc status and presence of infection and/or anthropometric indicators [2, 93, 94] . Four studies assessed serum zinc levels among children with diarrhea and matching controls [95] [96] [97] [98] .
The studies found that serum zinc was lower among children with an active infection than among control children.
Summary and discussion
Zinc deficiency is now widely recognized as a leading risk factor for morbidity and mortality; however, accurately assessing individual zinc deficiency remains challenging [4, 99] . The results of zinc supplementation trials show positive effects of zinc on functional outcomes, including infectious disease morbidity, growth, and development. These data are important for the treatment and prevention of illnesses in young children and should lead to interventions that include zinc in supplementation or food-based interventions. Evaluating the therapeutic response to zinc supplementation as assessed by randomized trials would be useful to determine population-level zinc deficiency. However, continuing trials with a policy for supplementation during contemporaneous diarrhea treatment would be unethical, and therefore, additional data will not be available. Zinc deficiency can lead to increased rates of diarrhea and pneumonia, but the rates of these diseases are variable between and within individual countries. The effect of zinc deficiency on the incidence and prevalence rates of diarrhea is not so great that it could be used to distinguish populations or groups likely to be deficient. However, it is possible to expect that populations with the highest rates of diarrhea would be more likely to have higher rates of zinc deficiency because of losses of zinc in the stools. The effects of zinc deficiency on child development are not consistent and are too difficult to measure to be useful as a population indicator.
It is well known that zinc deficiency can lead to growth retardation [1] . Brown et al. previously showed that children receiving zinc supplementation responded positively, especially when they were underweight or stunted at baseline [7] . Additional analysis of the results from growth trials confirms that we will expect to see the greatest response to supplementation in populations with the highest rates of stunting. Stunting rates of 20% and higher are considered a public health concern by the World Heath Organization [100] , and this value was recommended as a realistic cutoff to estimate problematic zinc deficiency within a population [4] . The additional investigation presented in this review supports these findings and recommendations for using stunting rates as the best approximation for estimating zinc deficiency at the population level for children under 5 years of age.
